Influenza Attack Rates and Vaccine Effectiveness by Prior-Season Infection and Vaccination: A 17-Season Analysis [0.03%]
既往感染和疫苗接种史对流感发病风险和疫苗效果的影响——基于17季的分析
Naoki Kawai,Takuma Bando,Takashi Kawashima et al.
Naoki Kawai et al.
Background: Vaccine effectiveness (VE) is commonly interpreted as a measure of protection but may be influenced by differences in baseline risk across populations. The effects of prior-season influenza infection and vacci...
Protective effects of influenza B neuraminidase antibodies against symptomatic influenza virus infection [0.03%]
流感病毒抗体对有症状的流感病毒感染的保护作用
Skyler Rogers,Kelsey M Sumner,Yangyupei Yang et al.
Skyler Rogers et al.
Background: Influenza vaccines are designed to induce hemagglutinin-inhibiting (HAI) antibodies rather than neuraminidase-inhibiting (NAI) antibodies; therefore, NAI antibodies' protective effects need further investigati...
Watching the Ship, Missing the Forest: Why Ecological Spillover, Reservoir Ecology, and Environmental Change Remain the True Hantavirus Threats in North America [0.03%]
顾此失彼：为什么生态溢出、宿主生态和环境变化才是北美的汉坦病毒的真正威胁
Lauren E Charles,Jennifer B Nuzzo,Natasha Bagdasarian
Lauren E Charles
The Effect of Prevaccination Analgesics on Influenza Vaccine Immunogenicity and Effectiveness [0.03%]
疫苗接种前使用镇痛剂对流感疫苗免疫原性和效力的影响
Carlie N Skellington,Kat Schmidt,Christina Schofield et al.
Carlie N Skellington et al.
Background: Analgesic medications are sometimes taken prior to vaccination to prevent local and systemic adverse reactions. Although studies have examined the association between postvaccination analgesic use and immunoge...
Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345 RSV Vaccine Administered 24 Months Following a Primary Dose in Adults ≥60 Years of Age [0.03%]
在≥60岁成人中接种单剂RSV mRNA疫苗24个月后，同一种疫苗加强剂的安全性、耐受性和免疫原性：一项概念验证试验
Mihir Desai,Gilberto Jimenez,Priyantha Wijewardane et al.
Mihir Desai et al.
Background: mRNA-1345 is a respiratory syncytial virus (RSV) vaccine approved for prevention of RSV-associated lower respiratory tract disease in individuals aged ≥60 years and those aged 18-59 years at high-risk of seve...
Epidemiology and molecular evolution of norovirus GII.17 in the United States, 2021-2025 [0.03%]
美国2021至2025年诺如病毒GII.17的流行病学及分子进化特征
Leslie Barclay,Mary E Wikswo,Helen Wall et al.
Leslie Barclay et al.
Background: GII.4 noroviruses have been the leading cause of acute gastroenteritis outbreaks in the United States (U.S.) for the past decade. Recently, GII.17 viruses have emerged globally, raising concerns about changes ...
Seroprevalence of Measles, Mumps, Rubella, and Varicella-Zoster Virus Antibodies-United States, 2017-March 2020 [0.03%]
2017年3月～2020年美国麻疹、腮腺炎、风疹和水痘-带状疱疹病毒抗体血清流行率
Chelsea S Lutz,Patricia Castro-Roman,Mona Marin et al.
Chelsea S Lutz et al.
Background: The most recent assessment of antibodies against measles, mumps, rubella, and varicella-zoster viruses (MeV, MuV, RuV, VZV) in the United States was conducted in 2009-2010. Regular assessments are essential to...
Pharyngeal gonorrhea in Ugandan men with urogenital gonorrhea: differences in antimicrobial resistance and strain types between anatomical sites [0.03%]
乌干达男性尿道淋病患者咽部感染情况及其解剖部位的药物耐受性差异和菌株类型分布差异
Johan H Melendez,Annet A Onzia,Emmanuel Mande et al.
Johan H Melendez et al.
Background: Pharyngeal Neisseria gonorrhoeae (phNG) infections are difficult to treat and contribute to antimicrobial resistance (AMR) in NG, but studies on phNG and differences with urogenital NG (uNG) are limited. ...